secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vaxcyte, Inc. (PCVX)
CIK:        0001649094
Form:       8-K
Filed at:   2026-02-24T23:59:59+00:00
Accession:  0001649094-26-000005
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaxcyte reports 2025 net loss of $766.6M; cash $2.44B plus $600M from Feb equity offering
--------------------------------------------------------------------------------

- Full-year 2025 net loss $766.6M vs $463.9M in 2024; R&D expenses $794.3M (up 67% YoY).
- Cash, equivalents, investments $2.44B at Dec 31, 2025; $632.5M gross from Feb 2026 public offering.
- VAX-31 adult Phase 3 program (OPUS-1/2/3) underway; topline OPUS-1 data expected Q4 2026, OPUS-2/3 in H1 2027.
- VAX-31 infant Phase 2 dose-finding study (900 infants) fully enrolled; data from series and booster expected by H1 2027.
- Plan to initiate Phase 1 study for Group A Strep vaccine candidate VAX-A1 in 2026; dedicated Lonza facility completed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649094/000164909426000005/0001649094-26-000005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649094/000164909426000005/pcvx-20260224.htm
  HTML page:      https://secwatch.observer/filing/0001649094-26-000005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer